Colon Grace 4

What Happened
Colon Grace, a director of Voyager Therapeutics, received a grant of 30,000 stock options (reported as a derivative security) on 2026-06-09. The filing reports a $0.00 price per share for the award (i.e., the grant is recorded with no cash purchase price in the Form 4). No immediate sale or purchase of underlying shares occurred — this is an option/award grant, not an open-market trade.

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-11.
• Transaction type/code: A (Grant/Award); security class: derivative (stock option).
• Quantity: 30,000 options; reported price: $0.00 per share.
• Shares owned after transaction: not specified in the provided filing data.
• Footnote: The options were issued under Voyager’s 2025 Stock Incentive Plan. Vesting commencement date is the grant date; all underlying shares vest upon the earlier of (a) one-year anniversary of the grant or (b) the date of the next annual meeting of stockholders, in each case subject to continued service by the director.
• Exhibit included: Exhibit 24 (Power of Attorney).
• Timeliness: Filed two days after the transaction date (no indication of a late filing).

Context: This is a derivative award (an option grant) rather than an immediate purchase or sale of shares. The options vest on a relatively short schedule (up to one year or next annual meeting) subject to continued service; if and when exercised, the transaction would create actual share ownership and could be reported separately (e.g., on a later Form 4). This type of director compensation is common and does not by itself indicate the director is buying or selling stock in the open market.